Head and Neck Neuroendocrine Carcinoma — Trials

Head and Neck Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 27
Recruiting: 10
Ph III recruiting: 1
Growth YoY: —
Industry share: 30%
Top sponsor: Eli Lilly and Company
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 101–108 of 108 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00134043	Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer	completed	Phase 2	19	National Cancer Institute (NCI)NIH	1	Aug 11, 2014	clinicaltrials
NCT01736878	Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma(SUMMIT)	withdrawn	Phase 2	0	Eanm Research LtdNETWORK	1	May 17, 2013	clinicaltrials